V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 10008563 | 10008640 | 1.61 | 49.7 | Curative (C) | 2016-12-19 | 2017-02-20 | VEDex | 02 | N | 10549203 | TRIFLURIDINE + TIPIRACIL |
| 10008564 | 10005325 | 1.76 | 70.4 | Palliative (P) | 2014-11-07 | 2014-11-07 | AML 18 TRIAL | 02 | N | 10549795 | CISPLATIN + GEMCITABINE |
| 10008565 | 10005326 | 1.75 | 51.5 | null | 2018-09-01 | 2018-09-07 | FEC | 2 | N | 10549872 | LIPOSOMAL DOXORUBICIN |
| 10008566 | 10007648 | 1.71 | 86.3 | Curative (C) | 2018-07-30 | 2018-08-09 | Bortezomib + CYCLOPHOSPHAMIDE | N | N | 10550104 | BORTEZOMIB + THALIDOMIDE |
| 10008567 | 10005330 | 1.75 | null | Disease modification (D) | null | 2018-08-24 | Carboplatin + Liposomal Doxorubicin | 02 | N | 10550149 | LIPOSOMAL DOXORUBICIN |
| 10008568 | 10005333 | null | 81.5 | Palliative (P) | 2018-10-02 | 2018-10-14 | Panitumumab | N | Y | 10550166 | CHLORAMBUCIL |
| 10008569 | 10007652 | 1.57 | 60.1 | Palliative (P) | 2017-01-24 | 2017-01-31 | Docetaxel + Nintedanib | 02 | N | 10550423 | CISPLATIN + GEMCITABINE |
| 10008570 | 10005339 | null | 63.7 | Neo-adjuvant (N) | null | 2017-07-17 | Carboplatin + Docetaxel | null | N | 10551288 | GEFITINIB |
| 10008571 | 10005340 | 1.55 | null | Adjuvant (A) | 2018-05-02 | 2018-05-03 | Docetaxel + Nintedanib | 02 | Y | 10551303 | VINORELBINE |
| 10008572 | 10007654 | 1.6 | 57.4 | Palliative (P) | 2018-04-01 | 2018-08-03 | Chlorambucil | N | null | 10551376 | DABRAFENIB |
| 10008573 | 10005342 | 1.81 | 80.6 | Palliative (P) | 2017-05-15 | 2017-05-15 | BORTEZOMIB + THALIDOMIDE | N | N | 10551778 | CYTARABINE + METHOTREXATE + RITUXIMAB + THIOTEPA |
| 10008574 | 10007656 | 1.74 | 81 | Palliative (P) | 2018-03-08 | 2018-03-21 | Trifluridine + Tipiracil | N | N | 10552352 | ERLOTINIB |
| 10008575 | 10007658 | 1.82 | 70 | Curative (C) | 2015-11-23 | 2015-12-11 | CABOZANTINIB | N | N | 10552953 | BENDAMUSTINE |
| 10008576 | 10005352 | 1.78 | 95 | Palliative (P) | 2015-12-21 | 2016-01-24 | Gemcitabine + Capecitabine | 2 | N | 10553837 | CETUXIMAB + IRINOTECAN |
| 10008577 | 10005353 | 1.7 | 69.6 | null | 2017-09-23 | 2017-09-28 | CETUXIMAB + OXALIPLATIN + MDG | N | N | 10553903 | FLUDARABINE |
| 10008578 | 10005353 | 1.76 | 93 | Palliative (P) | 2016-03-29 | 2016-04-08 | Bortezomib +/- Dexamethasone | 02 | Y | 10553903 | CAPECITABINE + CISPLATIN + EPIRUBICIN |
| 10008579 | 10007661 | 1.61 | 71.7 | Disease modification (D) | 2016-02-21 | 2016-02-24 | Bevacizumab+Carbo+Pacliaxel | N | N | 10554499 | ECX |
| 10008580 | 10005356 | 1.6 | 75.5 | Adjuvant (A) | 2017-09-02 | 2017-09-09 | NIVOLUMAB | N | null | 10554676 | BUSULPHAN |
| 10008581 | 10007662 | null | null | Palliative (P) | 2019-09-14 | 2019-09-21 | FEC 100 + DOCETAXEL | N | null | 10554850 | MITOMYCIN INTRAVESICULAR |
| 10008582 | 10007664 | 1.51 | 60.8 | Palliative (P) | 2017-12-21 | 2017-12-21 | Bortezomib | N | N | 10556254 | CISPLATIN + GEMCITABINE |
| 10008583 | 10005362 | 1.88 | 60.1 | Palliative (P) | 2016-10-03 | 2016-10-03 | Cetuximab + FOLFIRI cycle 2 onwards | 02 | N | 10556484 | BEVACIZUMAB + CAPE + OXALIPLATIN |
| 10008584 | 10007666 | 1.53 | 85.4 | Curative (C) | 2018-12-30 | 2019-02-08 | FEC 60 or 75 | 02 | N | 10556888 | ETOPOSIDE + RITUXIMAB |
| 10008585 | 10008651 | 1.73 | 57 | Curative (C) | 2018-06-16 | 2018-06-24 | MaxiCHOP (>Cycle 2) | 2 | N | 10557484 | METHOTREXATE INTRATHECAL |
| 10008586 | 10005368 | 1.79 | 86.9 | Palliative (P) | 2019-04-28 | 2019-07-26 | Cisplatin + Etoposide po&iv 3 day | N | null | 10557618 | METHOTREXATE |
| 10008587 | 10005371 | null | 63 | Palliative (P) | 2019-06-19 | 2019-06-20 | Carboplatin + Liposomal Doxorubicin | N | N | 10558076 | MUK7 TRIAL |
| 10008588 | 10005373 | 1.86 | 80 | Adjuvant (A) | null | 2016-06-07 | Erlotinib | N | N | 10558140 | BORTEZOMIB |
| 10008589 | 10005376 | 1.74 | null | Adjuvant (A) | 2018-11-09 | 2018-12-22 | Bevacizumab + CAPECITABINE + OXALIPLATIN | N | null | 10558553 | VINORELBINE |
| 10008590 | 10005376 | 1.73 | 77.9 | Palliative (P) | 2018-02-19 | 2018-02-20 | CAPECITABINE + EPIRUBICIN + OXALIPLATIN | N | N | 10558553 | CYCLOPHOSPHAMIDE + ETOPOSIDE + LOMUSTINE |
| 10008591 | 10005379 | null | 79.8 | Palliative (P) | 2018-06-24 | 2018-07-15 | Erlotinib | N | Y | 10558965 | IBRUTINIB + RITUXIMAB |
| 10008592 | 10005382 | 1.77 | 0 | Adjuvant (A) | 2017-08-19 | 2017-08-21 | CYCLOPHOSPHAMIDE + ETOPOSIDE + Procarbazine | 02 | N | 10559462 | CRIZOTINIB |
| 10008593 | 10005384 | 1.65 | 84 | Not known (9) | 2017-10-14 | 2017-11-08 | R ABVD | 2 | N | 10559587 | BUSULPHAN |
| 10008594 | 10007676 | 1.64 | 82.7 | Curative (C) | 2017-05-02 | 2017-06-01 | PROCAID TRIAL | 2 | N | 10559741 | CETUXIMAB |
| 10008595 | 10007678 | null | 62 | Palliative (P) | 2014-12-15 | 2015-05-18 | Capecitabine (21 day) + Irinotecan | 2 | N | 10560736 | DOXORUBICIN + IFOSFAMIDE |
| 10008596 | 10005390 | null | 75.2 | Palliative (P) | 2019-04-01 | 2019-04-03 | NIVOLUMAB | N | N | 10561026 | CAPECITABINE + CISPLATIN + EPIRUBICIN |
| 10008597 | 10005395 | 1.6 | 81.6 | Adjuvant (A) | 2017-11-20 | 2017-11-27 | Enzalutamide | 2 | N | 10562676 | CISPLATIN + GEMCITABINE |
| 10008598 | 10005397 | 1.73 | 78.5 | Palliative (P) | 2018-08-07 | 2018-08-07 | Pazopanib | 02 | N | 10562814 | MITOMYCIN INTRAVESICULAR |
| 10008599 | 10005403 | 1.65 | 86.65 | Palliative (P) | 2018-08-29 | 2018-09-10 | CYTARABINE + METHOTREXATE + RITUXIMAB + THIOTEPA | 02 | Y | 10563143 | PMITCEBO R |
| 10008600 | 10005404 | 1.72 | 84.2 | Palliative (P) | 2017-02-24 | 2017-04-28 | BORTEZOMIB + THALIDOMIDE | N | N | 10563223 | CISPLATIN + VINORELBINE + RT |
| 10008601 | 10005406 | 1.57 | 69.8 | Palliative (P) | 2016-12-29 | 2017-01-01 | Cetuximab 14 day | 02 | N | 10563459 | ETOPOSIDE + RITUXIMAB |
| 10008602 | 10005408 | 1.51 | 49.1 | Disease modification (D) | 2019-03-20 | 2019-03-21 | CETUXIMAB + IRINOTECAN + MDG | 2 | N | 10563630 | PANITUMUMAB |
| 10008603 | 10005409 | 0 | 72.3 | Palliative (P) | 2014-01-18 | 2014-01-19 | PCV | N | N | 10564423 | CAPECITABINE + RT |
| 10008604 | 10005410 | 1.77 | null | Palliative (P) | 2016-05-28 | 2016-07-02 | CISPLATIN + FLUOROURACIL | 01 | N | 10564461 | CAPECITABINE + CISPLATIN + RT |
| 10008605 | 10005411 | 1.66 | 61 | Disease modification (D) | 2019-08-21 | 2019-08-21 | DA-EPOCH-R | N | N | 10075763 | CISPLATIN + PEMETREXED |
| 10008606 | 10005413 | null | 68.6 | null | 2017-06-16 | 2018-02-24 | CISPLATIN + GEMCITABINE | 02 | null | 10205861 | CAPECITABINE + GEMCITABINE |
| 10008607 | 10005414 | 1.64 | 49.5 | Palliative (P) | 2017-10-05 | 2017-10-19 | TRASTUZUMAB EMTANSINE | 02 | N | 10214598 | CARBOPLATIN + LIPOSOMAL DOX |
| 10008608 | 10005417 | 1.65 | 64 | Palliative (P) | 2014-12-03 | 2014-12-17 | VEDex | N | Y | 10223520 | BEVACIZUMAB + CARBOPLATIN + PACLITAXEL |
| 10008609 | 10005420 | 1.74 | 94.7 | Palliative (P) | 2018-08-12 | 2018-09-09 | Gemcitabine + Capecitabine | 2 | N | 10226706 | ERLOTINIB |
| 10008610 | 10007695 | 1.53 | 65 | Palliative (P) | 2018-03-30 | 2018-03-30 | CYCLOPHOSPHAMIDE + DOCETAXEL + EPIRUBICIN + FLUOROURACIL + Trastuzumab | 02 | N | 10240541 | CYCLOPHOSPHAMIDE + DOCETAXEL |
| 10008611 | 10005427 | 1.61 | 65.8 | Palliative (P) | 2018-01-16 | 2018-01-22 | FCR Oral - Cycle 1 | N | N | 10241457 | MPV |
| 10008612 | 10008660 | 1.73 | 90.999 | Palliative (P) | 2017-03-21 | 2017-03-28 | LEAM | 02 | N | 10243822 | DOXORUBICIN + IFOSFAMIDE |